These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 4830322)

  • 1. [Personal experience with prolonged-action fluphenazine].
    Król K; Krystof J
    Psychiatr Pol; 1974; 8(2):149-55. PubMed ID: 4830322
    [No Abstract]   [Full Text] [Related]  

  • 2. Our experience with Moditene-Depot in chronic schizophrenia.
    Gamkrelidze ShA; Putkoradze-Gamkrelidze NA
    Act Nerv Super (Praha); 1973 Aug; 15(3):169. PubMed ID: 4769133
    [No Abstract]   [Full Text] [Related]  

  • 3. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
    Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619
    [No Abstract]   [Full Text] [Related]  

  • 4. [Characteristics of the psychotropic activity of long-acting drugs (experience in the use of Moditen-depot)].
    Smulevich AB; Minsker EI; Mazaeva NA; Volkova RP; Lukanina SK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(6):912-20. PubMed ID: 5050051
    [No Abstract]   [Full Text] [Related]  

  • 5. Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings].
    Schooler NR; Levine J; Severe JB
    Psychopharmacol Bull; 1979 Apr; 15(2):44-7. PubMed ID: 373006
    [No Abstract]   [Full Text] [Related]  

  • 6. [Experience with depot neuroleptics].
    Arató M; Erdós A
    Orv Hetil; 1979 Apr; 120(17):1015-21. PubMed ID: 372888
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical observation on the effect of domestic fluphenazine decanoate in the treatment of schizophrenia---report of 431 cases (author's transl)].
    Zhang YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Aug; 14(3):182-5. PubMed ID: 7333179
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of fluphenazine use since establishment of a psychiatric section].
    Roger BM
    Ann Med Psychol (Paris); 1972 Apr; 1(4):550-5. PubMed ID: 4342755
    [No Abstract]   [Full Text] [Related]  

  • 9. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
    Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH; Gelder MG
    Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prolonged treatment of schizophrenic psychoses with depot-fluphenazine ("lyogen decanoate")].
    Bohacek N; Mihovilović M
    Neuropsihijatrija; 1968; 16(3):69-73. PubMed ID: 5195835
    [No Abstract]   [Full Text] [Related]  

  • 12. Experience with fluphenazine decanoate in the management of chronic schizophrenic outpatients.
    Gaby N; Lefkowitz D; Israel JR
    N C Med J; 1982 Sep; 43(9):641-4. PubMed ID: 6958987
    [No Abstract]   [Full Text] [Related]  

  • 13. The depot compounds moditen (fluphenazine) and IMAP (fluspirilene) in clinical practice.
    Faltus F
    Act Nerv Super (Praha); 1974 Aug; 16(3):167-8. PubMed ID: 4607824
    [No Abstract]   [Full Text] [Related]  

  • 14. Maintenance treatment of schizophrenia with long-acting fluphenazine.
    Niturad A; Ciurezu T; Cucu I
    Act Nerv Super (Praha); 1974 Aug; 16(3):167. PubMed ID: 4154028
    [No Abstract]   [Full Text] [Related]  

  • 15. [Policlinical schizophrenia therapy with longtime neuroleptic agent fluphenazine decanoate].
    Haase HJ; Steuer A; Knaack M
    Med Welt; 1973 Feb; 24(8):306-7. PubMed ID: 4688219
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prognostic significance of selected side effects occurring in the course of prolonged-action fluphenazine treatment].
    Koślacz A; Popkowska N; Kulesza E; Lysikowska-Prokop L; Marmurowska-Michalowska H; Perzyński J
    Psychiatr Pol; 1977; 11(2):159-64. PubMed ID: 887674
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experience with the depot neuroleptic LyogenR-depot].
    Bach O; Petermann H; Geppert V
    Psychiatr Neurol Med Psychol (Leipz); 1978 Sep; 30(9):563-6. PubMed ID: 733993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The position of the depot-neuroleptics in the therapy of chronic psychoses. Experience with fluphenazine-decanoate].
    Auch W
    Med Welt; 1970 Oct; 21(41):1785-8. PubMed ID: 5471981
    [No Abstract]   [Full Text] [Related]  

  • 19. [Trial at the guidance center of ixelles of a major neuroleptic drug: anatensol decanoate].
    Berliner J
    Acta Psychiatr Belg; 1974 May; 74(3):305-16. PubMed ID: 4455024
    [No Abstract]   [Full Text] [Related]  

  • 20. [Blood serum concentration of long-acting fluphenazine in patients with various forms of schizophrenia].
    Pempkowiak L; Januszkiewicz-Grabiasowa A; Góra S
    Psychiatr Pol; 1979; 13(1):1-8. PubMed ID: 419224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.